

## DAFTAR PUSTAKA

- Alberta JA, Springett GM, Rayburn H, Natoli TA, Loring J, Kreidberg JA et al.  
Role of the WT1 tumor suppressor in murine hematopoiesis. *Blood* 2003;  
101: 2570–2574.
- Almeida MI, Reis RM, Calin GA. MicroRNA history: Discovery, recent  
applications and next frontiers. *Mutat Res* 2011; 717: 1-8.
- Baird PN, Simmons PJ. Expression of the Wilms' tumor gene (WT1) in normal  
hemopoiesis. *Exp Hematol* 1997; 25: 312–320.
- Barragán E, Cervera J, Bolufer P, Ballester S, Martín G, Fernández P, Collado R,  
Sayas MJ, Sanz MA. Prognostic implications of Wilms' tumor gene  
(WT1) expression in patients with de novo acute myeloid leukemia.  
*Haematologica* 2004; 89: 926–933.
- Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E et al.  
High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid  
leukemias are associated with a worse long-term outcome. *Blood* 1997;  
90: 1217–1225.
- Bhagavathi S, Czader M. MicroRNAs in Benign and Malignant Hematopoiesis.  
*Arch Pathol Lab Med* 2010; 134: 1276-1281.
- Boyapati A, Kanbe E, Zhang DE. p53 alterations in myeloid leukemia. *Acta  
Haematol* 2004; 111: 100–106.
- Brieger J, Weidmann E, Fenchel K, Mitrou PS, Hoelzer D, Bergmann L. The  
expression of the Wilms' tumor gene in acute myelocytic leukemias as a  
possible marker for leukemic blast cells. *Leukemia* 1994; 8: 2138–2143.

- Brieger J, Weidmann E, Fenchel K, Mitrou PS, Hoelzer D, Bergmann L. The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. *Leukemia* 1994; 8: 2138–2143.
- Chiusa L, Francia di Celle P, Campisi P, Ceretto C, Marmont F, Pich A. Prognostic value of quantitative analysis of WT1 gene transcripts in adult acute lymphoblastic leukemia. *Haematologica* 2006; 91: 270–271.
- Cilloni D, Gottardi E, Micheli DD, Serra A, Volpe G, Messa F, Rege-Cambrin G, Guerrasio A, Divona M, Coco FL, Saglio G. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. *Leukemia* 2001; 16: 2115-2121.
- Cilloni D, Gottardi E, Saglio G. WT1 Overexpression in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Dalam: Iland, H, Hertzberg, M & Marlton, P (editor) *Myeloid Leukemia: Methods and Protocols*. Edisi 1. New Jersey: Humana Press; 2006.
- Cilloni D, Messa F, Arruga F, Defilippi I, Gottardi E, Fava M, Carturan S, Catalano R, Bracco E, Messa E, Nicoli P, Diverio D, Sanz MA, Martinelli G, Lo-Coco F, Saglio G. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. *Hematologica* 2008; 93: 921-924.
- Cook DM, Hinkes MT, Bernfield M, Rauscher III FJ. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1. *Oncogene* 1996; 13: 1789–1799.

Dame C, Kirschner KM, Bartz KV, Wallach T, Hussels CS, Scholz H. Wilms tumor suppressor, Wt1, is a transcriptional activator of the erythropoietin gene. *Blood* 2006; 107: 4282–4290.

Dejong V, Degeorges A, Filleur S, Ait-Si-Ali S, Mettouchi A, Bornstein P et al. The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun. *Oncogene* 1999; 18: 3143–3151.

Dennis SL1, Manji SS, Carrington DP, Scarcella DL, Ashley DM, Smith PJ, Algar EM. The Wilms' tumor 1 gene in human neural tumors. *Int J Cancer* 2002; 97: 713–715.

Deuel TF, Guan LS, Wang ZY. Wilms' tumor gene product WT1 arrests macrophage differentiation of HL-60 cells through its zinc-finger domain. *Biochem Biophys Res Commun* 1999; 254: 192–196.

Devillard E, Bladou F, Ramuz O, Karsenty G, Dales JP, Gravis G et al. FGFR1 and WT1 are markers of human prostate cancer progression. *BMC Cancer* 2006; 6: 272.

Dey BR, Sukhatme VP, Roberts AB, Sporn MB, Rauscher III FJ, Kim SJ. Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product. *Mol Endocrinol* 1994; 8: 595–602.

Drummond IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP, Rauscher III FJ. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. *Science* 1992; 257: 674–678.

Dupont J, Wang X, Marshall DS, Leitao M, Hedvat CV, Hummer A et al. Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a

study of 130 cases using a tissue microarray. *Gynecol Oncol* 2004; 94: 449–455|

Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. *EMBO J* 2001; 20: 1897–1909.

Englert C, Maheswaran S, Garvin AJ, Kreidberg J, Haber DA. Induction of p21 by the Wilms' tumor suppressor gene WT1. *Cancer Res* 1997; 57: 1429–1434.

Gaiger A, Schmid D, Heinze G, Linnerth B, Greinix H, Kalhs P et al. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. *Leukemia* 1998; 12: 1886–1894.

Garg M, Moore H, Tobal K, Liu Yin JA. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. *Br J Haematol* 2003; 123: 49–59.

Gashler AL, Bonthron DT, Madden SL, Rauscher III FJ, Collins T, Sukhatme VP. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. *Proc Natl Acad Sci USA* 1992; 89: 10984–10988.

Gianfaldoni G, Mannelli F, Ponziani V, Longo G, Bencini S, Bosi A, Vannucchi AM. Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. *Hematologica* 2010; 95: 833-836.

Goodyer P, Dehbi M, Torban E, Bruening W, Pelletier J. Repression of the retinoic acid receptor-alpha gene by the Wilms' tumor suppressor gene product, wt1. *Oncogene* 1995; 10: 1125–1129.

Gu W, Chen Z, Hu S, Shen H, Qiu G, Cao X. Changes in expression of WT1 isoforms during induced differentiation of the NB4 cell line. *Haematologica* 2005; 90: 403–405.

Han Y, San-Marina S, Liu J, Minden MD. Transcriptional activation of c-myc proto-oncogene by WT1 protein. *Oncogene* 2004; 23: 6933–6941.

Harrington MA, Konicek B, Song A, Xia XL, Fredericks WJ, Rauscher III FJ. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. *J Biol Chem* 1993; 268: 21271–21275.

Hewitt SM, Hamada S, McDonnell TJ, Rauscher III FJ, Saunders GF. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. *Cancer Res* 1995; 55: 5386–5389.

Hohenstein P, Hastie ND. The many facets of the Wilms' tumour gene, WT1. *Hum Mol Genet* 2006; 15: R196-R201.

Hosen N, Sonoda Y, Oji Y, Kimura T, Minamiguchi H, Tamaki H et al. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells. *Br J Haematol* 2002; 116: 409–420.

Hosono S, Gross I, English MA, Hajra KM, Fearon ER, Licht JD. E-cadherin is a WT1 target gene. *J Biol Chem* 2000; 275: 10943–10953.

Hossain A, Nixon M, Kuo MT, Saunders GF. N-terminally truncated WT1 protein with oncogenic properties overexpressed in leukemia. *J Biol Chem* 2006; 281: 28122–28130.

Hou HA, Huang TC, Lin LI, Liu CY, Chen CY, Chou WC, Tang JL, Tseng MH, Huang CF, Chiang YC, Lee FY, Liu MC, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. *Blood* 2010; 115: 5222-5231.

Idelman G, Glaser T, Roberts Jr CT, Werner H. WT1-p53 interactions in insulin-like growth factor-I receptor gene regulation. *J Biol Chem* 2003; 278: 3474–3482.

Ito K, Oji Y, Tatsumi N, Shimizu S, Kanai Y, Nakazawa T et al. Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway. *Oncogene* 2006; 25: 4217–4229.

Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C et al. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. *Mol Cell Biol* 1996; 16: 6945–6956.

Karakas T, Miething CC, Maurer U, Weidmann E, Ackermann H, Hoelzer D et al. The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia. *Leukemia* 2002; 16: 846–854.

King-Underwood L, Little S, Baker M, Clutterbuck R, Delassus S, Enver T et al.

WT1 is not essential for hematopoiesis in the mouse. *Leuk Res* 2005; 29:  
803–812.

King-Underwood L, Renshaw J, Pritchard-Jones K. Mutations in the Wilms'  
tumor gene WT1 in leukemias. *Blood* 1996; 87: 2171–2179.

Kresno, S. B. Micro-RNA dan Implikasinya pada Kanker. *Indonesian Journal of  
Cancer* 2011; 5: 119-127.

Lee SB, Huang K, Palmer R, Truong VB, Herzlinger D, Kolquist KA et al. The  
Wilms tumor suppressor WT1 encodes a transcriptional activator of  
amphiregulin. *Cell* 1999; 98: 663–673.

Li RS, Law GL, Seifert RA, Romaniuk PJ, Morris DR. Ornithine decarboxylase is  
a transcriptional target of tumor suppressor WT1. *Exp Cell Res* 1999; 247:  
257–266.

Loeb DM, Korz D, Katsnelson M, Burwell EA, Friedman AD, Sukumar S. Cyclin  
E is a target of WT1 transcriptional repression. *J Biol Chem* 2002; 277:  
19627–19632.

Maheswaran S, Englert C, Bennett P, Heinrich G, Haber DA. The WT1 gene  
product stabilizes p53 and inhibits p53-mediated apoptosis. *Genes Dev*  
1995; 9: 2143–2156.

Malagola M, Skert C, Ruggeri G, Turra A, Ribolla R, Cancelli V, Cattina F,  
Alghisi E, Bernardi S, Perucca S, Palma AD, Borlenghi E, Pagani C, Rossi  
G, Caimi L, Russo D. Peripheral Blood WT1 Expression Predicts Relapse  
in AML Patients Undergoing Allogeneic Stem Cell Transplantation.  
*BioMed Research International* 2014, 2014: 5 halaman.

Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrózek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH, Schwind S, Becker H, Einfeld AK, Carroll AJ, Powell BL, Kolitz JE, Garzon R, Caligiuri MA, Stone RM, Bloomfield CD. Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients. *J Clin Oncol* 2013; 31: 2086-2093.

McCann S, Sullivan J, Guerra J, Arcinas M, Boxer LM. Repression of the c-myc gene by WT1 protein in T and B cell lines. *J Biol Chem* 1995; 270: 23785–23789.

Menke AL, Shvarts A, Riteco N, van Ham RCA, van der Eb AJ, Jochemsen AG. Wilms' Tumor 1-KTS Isoforms Induce p53-independent Apoptosis That Can Be Partially Rescued by Expression of the Epidermal Growth Factor Receptor or the Insulin Receptor. *Cancer Res* 1997; 57: 1353-1363.

Menke AL, van der Eb AJ, Jochemsen AG. The Wilms' tumor 1 gene: oncogene or tumor suppressor gene? *Int Rev Cytol* 1998; 181: 151–212.

Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S et al. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. *Leukemia* 1995; 9: 1060–1067.

Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. *Leukemia* 1992; 6: 405–409.

Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koeffler HP, Miyoshi I. Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells.

*Leukemia* 1993; 7: 970–977.

Morrison DJ, English MA, Licht JD. WT1 Induces Apoptosis through Transcriptional Regulation of the Proapoptotic Bcl-2 Family Member Bak.

*Cancer Res* 2005; 65: 8174-8182.

Moshier JA, Skunca M, Wu W, Boppana SM, Rauscher III FJ, Dosesu J.

Regulation of ornithine decarboxylase gene expression by the Wilms' tumor suppressor WT1. *Nucleic Acids Res* 1996; 24: 1149–1157.

Nichols KE, Re GG, Yan YX, Garvin AJ, Haber DA. WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells. *Cancer Res* 1995; 55: 4540–4543.

Nishida S, Hosen N, Shirakata T, Kanato K, Yanagihara M, Nakatsuka S et al.

AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. *Blood* 2006; 107: 3303–3312.

Nyvold CG, Stentoft J, Braendstrup K, Melsvik D, Moestrup SK, Juhl-

Christensen C et al. Wilms' tumor 1 mutation accumulated during therapy in acute myeloid leukemia: Biological and clinical implications. *Leukemia*

2006; 20: 2051–2054.

Oh S, Song Y, Yim J, Kim TK. The Wilms' tumor 1 tumor suppressor gene

represses transcription of the human telomerase reverse transcriptase gene.

*J Biol Chem* 1999; 274: 37473–37478.

Ostergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene

expression: an excellent tool for monitoring minimal residual disease in

70% of acute myeloid leukaemia patients - results from a single-centre study. *Br J Haematol* 2004; 125: 590–600.

Palma CA, Al Sheikha D, Lim TK, Bryant A, Vu TT, Jayaswal V, Ma DD. MicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia. *Mol Cancer* 2014; 13: 79-93.

Phelan SA, Lindberg C, Call KM. Wilms' tumor gene, WT1, mRNA is down-regulated during induction of erythroid and megakaryocytic differentiation of K562 cells. *Cell Growth Differ* 1994; 5: 677–686.

Polák J, Hájková H, Maaloufová-Soukupová J, Marková J, Sálek C, Schwarz J, Haškovec C. Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression. *Exp Ther Med* 2011; 3: 129-133.

Ryan G, Steele-Perkins V, Morris JF, Rauscher III FJ, Dressler GR. Repression of Pax-2 by WT1 during normal kidney development. *Development* 1995; 121: 867–875.

Saini HK, Griffiths-Jones S, Enright AJ. Genomic analysis of human microRNA transcripts. *Proc Natl Acad Sci U S A* 2007; 104: 17713-17724.

Sakamoto Y, Yoshida M, Semba K, Hunter T. Inhibition of the DNA-binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of Ser-365 and Ser-393 in the zinc finger domain. *Oncogene* 1997; 15: 2001–2012.

Schmid D, Heinze G, Linnerth B, Tisljar K, Kusec R, Geissler K et al. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. *Leukemia* 1997; 11: 639–643.

Sen CK, Gordillo GM, Khanna S, Roy S. Micromanaging Vascular Biology: Tiny

MicroRNAs Play Big Band. *J Vasc Res* 2009; 46(6): 527-540.

Sim EU, Smith A, Szilagi E, Rae F, Ioannou P, Lindsay MH et al. Wnt-4

regulation by the Wilms' tumour suppressor gene, WT1. *Oncogene* 2002;  
21: 2948–2960.

Slack FJ, Weidhaas JB. MicroRNA in Cancer Prognosis. *N Engl J Med* 2008;

359: 2720-2722.

Smith SI, Down M, Boyd AW, Li CL. Expression of the Wilms' tumor suppressor

gene, WT1, reduces the tumorigenicity of the leukemic cell line M1 in  
C.B-17 scid/scid mice. *Cancer Res* 2000; 60: 808–814.

Sugiyama H. Cancer immunotherapy targeting Wilms' tumor gene WT1 product.

*Expert Rev Vaccines* 2005; 4: 503–512.

Svedberg H, Chylicki K, Baldetorp B, Rauscher III FJ, Gullberg U. Constitutive

expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937  
blocks parts of the differentiation program. *Oncogene* 1998; 16: 925–932.

Svedberg H, Chylicki K, Gullberg U. Downregulation of Wilms' tumor gene

(WT1) is not a prerequisite for erythroid or megakaryocytic differentiation  
of the leukemic cell line K562. *Exp Hematol* 1999; 27: 1057–1062.

Svedberg H, Richter J, Gullberg U. Forced expression of the Wilms tumor 1

(WT1) gene inhibits proliferation of human hematopoietic CD34(+)  
progenitor cells. *Leukemia* 2001; 15: 1914–1922.

Svensson E, Eriksson H, Gekas C, Olofsson T, Richter J, Gullberg U. DNA-

binding dependent and independent functions of WT1 protein during  
human hematopoiesis. *Exp Cell Res* 2005; 308: 211–221.

Tamaki H, Ogawa H, Ohyashiki K, Ohyashiki JH, Iwama H, Inoue K et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. *Leukemia* 1999; 13: 393–399.

Udtha M, Lee SJ, Alam R, Coombes K, Huff V. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors. *Oncogene* 2003; 22: 3821–3826.

Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. *N Engl J Med* 2004; 350: 1617–1628.

Wagner KJ, Patek CE, Miles C, Christie S, Brookes AJ, Hooper ML. Truncation of WT1 results in downregulation of cyclin G1 and IGFBP-4 expression. *Biochem Biophys Res Commun* 2001; 287: 977–982.

Waldstrøm M1, Grove A. Immunohistochemical expression of wilms tumor gene protein in different histologic subtypes of ovarian carcinomas. *Arch Pathol Lab Med* 2005; 129: 85–88.

Wang ZY, Madden SL, Deuel TF, Rauscher III FJ. The Wilms' tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene. *J Biol Chem* 1992; 267: 21999–22002.

Wang ZY, Qiu QQ, Deuel TF. The Wilms' tumor gene product WT1 activates or suppresses transcription through separate functional domains. *J Biol Chem* 1993; 268: 9172–9175.

Ward A, Pooler JA, Miyagawa K, Duarte A, Hastie ND, Caricasole A. Repression of promoters for the mouse insulin-like growth factor II-encoding gene

(Igf-2) by products of the Wilms' tumour suppressor gene wt1. *Gene* 1995; 167: 239–243.

Webster NJ, Kong Y, Sharma P, Haas M, Sukumar S, Seely BL. Differential effects of Wilms tumor WT1 splice variants on the insulin receptor promoter. *Biochem Mol Med* 1997; 62: 139–150.

Werner H, Rauscher III FJ, Sukhatme VP, Drummond IA, Roberts Jr CT, LeRoith D. Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site. *J Biol Chem* 1994; 269: 12577–12582.

Werner H, Re GG, Drummond IA, Sukhatme VP, Rauscher III FJ, Sens DA et al. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. *Proc Natl Acad Sci USA* 1993; 90: 5828–5832.

Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. *Blood* 1996; 87: 2878–2884.

Yang L, Han Y, Saiz FS, Minden M.. A tumor suppressor and oncogene: the WT1 story. *Leukemia* 2007; 21, 868-876.

Ye Y, Raychaudhuri B, Gurney A, Campbell CE, Williams BR. Regulation of WT1 by phosphorylation: inhibition of DNA binding, alteration of

transcriptional activity and cellular translocation. *EMBO J* 1996; 15:  
5606–5615.

Zaia A, Fraizer GC, Piantanelli L, Saunders GF. Transcriptional regulation of the  
androgen signaling pathway by the Wilms' tumor suppressor gene WT1.  
*Anticancer Res* 2001; 21: 1–10.

Zhang R, Yang JY, Sun HQ, Jia H, Liao J, Shi YJ, Li G. (2015). Comparison of  
minimal residual disease (MRD) monitoring by WT1 quantification  
between childhood acute myeloid leukemia and acute lymphoblastic  
leukemia. *Eur Rev Med Pharmacol Sci* 2015; 19: 2679-2688.